S&P 500

7,574.08

+32.68

+0.43%

Dow 30

51,826.88

-157.10

-0.30%

Nasdaq

25,383.56

+219.20

+0.87%

Russell 2000

2,825.00

+19.13

+0.68%

10-Yr Bond

4.9500

+0.0560

+1.14%

VIX

20.62

-0.53

-2.50%

Gold

3,932.90

-36.70

-0.92%

Bitcoin USD

77,459.80

+508.33

+0.66%

Crude Oil Dec 26

95.96

-0.50

-0.52%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCPK - Delayed Quote USD

Santen Pharmaceutical Co., Ltd. (SNPHY)

11.82 +1.04 (+9.65%)

As of October 30 at 4:00:00 PM EDT. Market Open.

Loading Chart for SNPHY

Chart Range Bar

Interval:

In partnership with ChartIQ

Santen Pharmaceutical (TSE:4536) Stock Could Be Undervalued On Current Earnings

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

Mobilize your Website

View Site in Mobile | Classic

Share by:

U.S. markets close in 1h 26m

Santen Pharmaceutical Co., Ltd. (SNPHY)

Recent News

Santen Pharmaceutical (TSE:4536) Stock Could Be Undervalued On Current Earnings

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

Related Tickers